These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 12751445)

  • 1. HAART to heart talk.
    Huff B
    GMHC Treat Issues; 2003 Apr; 17(4):8-9. PubMed ID: 12751445
    [No Abstract]   [Full Text] [Related]  

  • 2. Antiretrovirals and cardiovascular disease: is HAART bad for your heart?
    Fichtenbaum CJ
    AIDS Clin Care; 2003 Aug; 15(8):69-73, 76. PubMed ID: 12945527
    [No Abstract]   [Full Text] [Related]  

  • 3. Cardiovascular disease and toxicities related to HIV infection and its therapies.
    Zareba KM; Miller TL; Lipshultz SE
    Expert Opin Drug Saf; 2005 Nov; 4(6):1017-25. PubMed ID: 16255661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Care of the HIV-positive patient in the emergency department in the era of highly active antiretroviral therapy.
    Venkat A; Piontkowsky DM; Cooney RR; Srivastava AK; Suares GA; Heidelberger CP
    Ann Emerg Med; 2008 Sep; 52(3):274-85. PubMed ID: 18358567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiretroviral therapy in HIV-infected children: the metabolic cost of improved survival.
    Leonard EG; McComsey GA
    Infect Dis Clin North Am; 2005 Sep; 19(3):713-29. PubMed ID: 16102657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What happens to children growing up with HIV infection? It's time for a HAART to heart.
    Viganò A; Pattarino G; Cerini C; Zuccotti GV
    Expert Rev Anti Infect Ther; 2009 Jun; 7(5):495-8. PubMed ID: 19485788
    [No Abstract]   [Full Text] [Related]  

  • 7. Highly active antiretroviral therapy-associated metabolic syndrome: pathogenesis and cardiovascular risk.
    Barbaro G
    Am J Ther; 2006; 13(3):248-60. PubMed ID: 16772767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New therapy strategies focusing on long term. Drugs' impact on heart is debated.
    AIDS Alert; 2003 Apr; 18(4):45-7. PubMed ID: 12710403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiretroviral therapy in HIV patients: aspects of metabolic complications and mitochondrial toxicity.
    ter Hofstede HJ; Burger DM; Koopmans PP
    Neth J Med; 2003 Dec; 61(12):393-403. PubMed ID: 15025414
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluation of cardiovascular risk in HIV patients: clinical implication.
    Das S
    Int J Clin Pract; 2010 Aug; 64(9):1173-5. PubMed ID: 20653794
    [No Abstract]   [Full Text] [Related]  

  • 11. [HIV infection: emerging issues and new challenges].
    Calza L; Manfredi R; Chiodo F
    Recenti Prog Med; 2006 Dec; 97(12):771-80. PubMed ID: 17252736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growing up with perinatal HIV infection: time for a HAART to heart.
    Siberry GK; Joyner M; Hutton N
    J Pediatr; 2008 Oct; 153(4):456-7. PubMed ID: 18847617
    [No Abstract]   [Full Text] [Related]  

  • 13. Insulin Resistance and the cardiometabolic syndrome in HIV infection.
    Bevilacqua M; Dominguez LJ; Barbagallo M
    J Cardiometab Syndr; 2009; 4(1):40-3. PubMed ID: 19245515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrovascular ischemic events in HIV-1-infected patients receiving highly active antiretroviral therapy: incidence and risk factors.
    Corral I; Quereda C; Moreno A; Pérez-Elías MJ; Dronda F; Casado JL; Muriel A; Masjuán J; Alonso-de-Leciñana M; Moreno S
    Cerebrovasc Dis; 2009; 27(6):559-63. PubMed ID: 19390181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lactic acidosis in Africans receiving HAART.
    Kemper CA
    AIDS Alert; 2007 Sep; 22(9):106-8. PubMed ID: 18411465
    [No Abstract]   [Full Text] [Related]  

  • 16. [HIV infection, antiretroviral therapy, and endothelium].
    Hürlimann D; Weber R; Enseleit F; Lüscher TF
    Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular risks in HIV patients.
    Hedner T; Oparil S; Narkiewicz K; Os I
    Blood Press; 2010 Dec; 19(6):325-7. PubMed ID: 21080761
    [No Abstract]   [Full Text] [Related]  

  • 18. Liver ultrastructural morphology and mitochondrial DNA levels in HIV/hepatitis C virus coinfection: no evidence of mitochondrial damage with highly active antiretroviral therapy.
    Matsukura M; Chu FF; Au M; Lu H; Chen J; Rietkerk S; Barrios R; Farley JD; Montaner JS; Montessori VC; Walker DC; Côté HC
    AIDS; 2008 Jun; 22(10):1226-9. PubMed ID: 18525271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up.
    Resino S; Resino R; Micheloud D; Gurbindo Gutiérrez D; Léon JA; Ramos JT; Ciria L; de José I; Mellado J; Muñoz-Fernández A;
    Clin Infect Dis; 2006 Mar; 42(6):862-9. PubMed ID: 16477566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How does HIV impact on non-AIDS events in the era of HAART?
    Barber TJ; Hughes A; Dinsmore WW; Phillips A
    Int J STD AIDS; 2009 Jan; 20(1):1-3. PubMed ID: 19103883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.